Supernus Pharmaceuticals
SUPN
#4381
Rank
A$3.83 B
Marketcap
A$66.16
Share price
-2.10%
Change (1 day)
29.41%
Change (1 year)

Earnings for Supernus Pharmaceuticals (SUPN)

Earnings in 2026 (TTM): -A$78.77 Million

According to Supernus Pharmaceuticals 's latest financial reports the company's current earnings are A$0.77 Billion. In 2025 the company made an earning of -A$70.22 Million a decrease over its 2024 earnings that were of A$0.11 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Supernus Pharmaceuticals from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -A$78.77 Million12.19%
2025 -A$70.22 Million-161.15%
2024 A$0.11 B1446.62%
2023 A$7.42 M-92.36%
2022 A$97.1 M-29.8%
2021 A$0.13 B-49.79%
2020 A$0.27 B12.99%
2019 A$0.24 B7.58%
2018 A$0.22 B54.9%
2017 A$0.14 B84.25%
2016 A$79.41 M202.27%
2015 A$26.27 M-462.04%
2014 -A$7.26 Million-94%
2013 -A$0.13 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
A$37.20 B-49,701.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
A$11.65 B-15,636.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$44.57 B-59,527.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$13.74 B-18,423.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Zogenix
ZGNX
-A$0.31 Billion 304.83%๐Ÿ‡บ๐Ÿ‡ธ USA
United Therapeutics
UTHR
A$2.32 B-3,202.82%๐Ÿ‡บ๐Ÿ‡ธ USA